BenzingaAugust 19, 2026 at 10:02 AM NY16 days ago
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO)
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill1 hour ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill1 hour ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo2 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo2 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo2 hours ago